A total of 68 articles were included in the final synthesis (corresponding to the reference list), comprising clinical trials and observational studies of GLP-1RA, mechanistic and immunology papers on GLP-1 signaling and metabolic inflammation, literature on autoimmune thyroid disease pathophysiology, adipokines, Non-alcoholic fatty liver disease (NAFLD)/Metabolic dysfunction-associated fatty liver disease (MAFLD)/Metabolic dysfunction-associated steatotic liver disease (MASLD)/Metabolic dysfunction-associated steatohepatitis (MASH), and gut-thyroid-microbiota interactions. Here, GLP1R is linked to metabolic dysfunction-associated steatotic liver disease.